A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL

Inclusion Criteria: * Subjects must meet the following inclusion criteria. * The subject must have a confirmed diagnosis of acute lymphoblastic leukemia within 1 week of starting therapy * Currently being treated on a standard ALL induction regimen * Subjects must be greater than or equal to 5 and less than 18 years old * Signed informed consent Exclusion Criteria: * Subjects will be excluded for the following: * Preexisting neurologic disease, including grade II, III, or IV neurological status by NCI Common Toxicity Criteria v3.0 on clinical exam * History of hypersensitivity to vincristine * History of hypersensitivity to Acetyl-L-carnitine * Previous use of Acetyl-L-carnitine * Concurrent anti-convulsant use * Concurrent Gabapentin use * Concurrent Glutamine use * Liver Function: Total bilirubin greater than 1.3 mg/dL and serum glutamic-pyruvic transaminase (SGPT) (ALT) greater than 5 x upper limit of normal for age and serum albumin less than 2 g/dL * Patients who are pregnant